Home / Healthcare / Angina Pectoris Treatment Market By Drug Type (Antiplatelet agents, Beta-adrenergic blocking agents, Calcium channel blockers, Short & Long – acting Nitroglycerines, Angiotensin-converting enzyme inhibitors, Anti-ischemic agents) - Growth, Share, Opportunities & Competitive Analysis, 2015 - 2022

Angina Pectoris Treatment Market By Drug Type (Antiplatelet agents, Beta-adrenergic blocking agents, Calcium channel blockers, Short & Long – acting Nitroglycerines, Angiotensin-converting enzyme inhibitors, Anti-ischemic agents) - Growth, Share, Opportunities & Competitive Analysis, 2015 - 2022

Published: Apr 2016 | Published By: Acute Market Reports

This report on global angina pectoris treatment market studies various drugs used for treatment of angina pectoris along with pipeline analysis of upcoming potential drugs. Angina is chest pain due to transient myocardial ischaemia, which usually occurs with physical activity or emotional stress, in the United States 10.2 million are estimated to experience angina with approximately 500,000 new cases occurring each year. Thus, drug pipeline of angina pectoris treatment market comprises potential drugs which are specific and fast in therapeutic action. 

For the purpose of this study, the various drug classes studied include antiplatelet agents, beta-adrenergic blocking agents, calcium channel blockers, short & long – acting nitroglycerines angiotensin-converting enzyme inhibitors and anti-ischemic agents. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

The pipeline analysis for angina pectoris treatment market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are Dantonic/T89 (Tasly Pharmaceuticals, Inc.), RANCAD (TSH Biopharm Corporation Limited), Cilostazol (Korea Otsuka Pharmaceutical Co.,Ltd.), Bococizumab (Pfizer, Inc.), Ticagrelor (J.M. ten Berg/ Astra Zeneca plc), Auto-CD34+ cells (Baxalta US Inc.) and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.

The geographic segmentation of the global angina pectoris market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

TABLE 1 Global Angina Pectoris Treatment Market Revenue, by Drug Class, 2013 – 2022 (USD Mn)
TABLE 2 Global Angina Pectoris Treatment Marrket Revenue, by Geography, 2013 – 2022 (USD Mn)
TABLE 3 North America Angina Pectoris Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 4 Europe Angina Pectoris Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 5 Asia - Pacific Angina Pectoris Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 8 Rest of the World Angina Pectoris Treatment Market Revenue, by Region, 2013 – 2022 (USD Mn)

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +